Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
Status:
Recruiting
Trial end date:
2025-11-11
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of capivasertib plus abiraterone
(+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus
abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are
characterised by PTEN deficiency. The intention of the study is to demonstrate that in
participants with mHSPC, the combination of capivasertib plus abiraterone
(+prednisone/prednisolone) plus ADT is superior to placebo plus abiraterone
(+prednisone/prednisolone) plus ADT in participants with mHSPC characterised by PTEN
deficiency with respect to radiographic progression-free survival (rPFS) per 1) Response
Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and/or Prostate Cancer
Working Group (PCWG3) for bone as assessed by the investigator 2) death due to any cause.